ClinicalTrials.gg
Enrolling by invitationNCT06729697Updated Apr 13, 2025

Pharmaceutical Literacy and Quality of Life in Spanish Population.

An observational study in Health Related Quality of Life and Literacy, sponsored by University of Barcelona. Enrolling by invitation at 1 site in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-04-13.

Sponsored by University of Barcelona · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2025, 1 year 4 months ago, but the record still lists the study as enrolling by invitation.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Cross-sectional
Enrollment
1,246
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this study is to learn about the knowledge and abilities that patients have regarding their own medication and to see if that's related to their quality of life.

The main questions it aims to answer are:

  • Are patients abilities and knowledge about their medications sufficient to ensure a safe and efective use?
  • Are those knowledge and abilities related to the patient's quality of life? How?

Patients already taking at least one medication will answer questions about their abilities and knowledge towards medication and their quality of life related to their health state.

Read the detailed description

A cross-sectional study is carried out, consisting of an interview between the patients and community pharmacists included in the study.

The participants selected are adults usually taking medication that answer questions related to their pharmaceutical literacy (RALPH interview). This type of literacy refers to three domains regarding functional, comunicative and critical abilities about their own medication.

After that, every participant answers a simple survey regarding their health-related quality of life including topics such as mobility, self-care, everyday activities, pain and mental health (EQ-5D-5L survey).

The recruitment and interviewing take place at the same time, and it requires less than 30 minutes per patient. No follow-up is needed afterward.

There are no risks associated with this procedure, and the participation of the patients will always be voluntary and anonymous.

Previously to the patients' enrollment in the study, proper information will be given to the potential participants and an informed consent will be signed.

02

Conditions studied

  • Health Related Quality of Life
  • Literacy

Browse trials for

Keywords

  • Pharmaceutical literacy
  • Health related quality of life
  • Spain
  • Community pharmacist
03

In context

Literacy

203 studies on the registry are indexed under Literacy; 69 are open to participants now.

This study's planned enrollment of 1,246 is above the median of 256 across 28 observational studies indexed under Literacy.

Browse Literacy studies →

Lead sponsor

University of Barcelona is the lead sponsor of 100 studies on the registry; 30 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adults taking at least one medication in Spain at the moment of the study.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults currently taking at least one medication prescribed by a physician and living in Spain.

Exclusion criteria

Exclusion Criteria:

  • Having physical or cognitive limitations that make it impossible to answer the study questions.
05

Study design

Observational model
Other
Time perspective
Cross-sectional
Enrollment
1,246 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Recognising and Addressing Limited Pharmaceutical Literacy (RALPH) interview guide score

    A quantitative score will be obtained after an interview using the RALPH guide for community pharmacy. Only correct answered questions will add a point to the score. The values obtained stand between 0 and 10, and a higher score means a better outcome.

    Time frame: Through study completion, an average of 1 year.

  2. EQ-5D-5L index score

    A health state index score will be calculated from individual health profiles using the Spanish value set (Roudijk B, Ludwig K, Devlin N, Roudijk B, Ludwig K, Devlin N. EQ-5D-5L Value Set Summaries. Value Sets for EQ-5D-5L. 2022;55-212.) where the values stand between -0.166 and 1, and a higher score means a better outcome.

    Time frame: Through study completion, an average of 1 year.

Secondary outcomes

  1. Sex

    Sex according to the categories: male or female.

    Time frame: Through study completion, an average of 1 year.

  2. Age

    Age in years.

    Time frame: Through study completion, an average of 1 year.

  3. Country of birth

    Name of the country of birth.

    Time frame: Through study completion, an average of 1 year.

  4. Level of education

    Education level according to the 4 categories: uneducated, primary education, secondary education and higher education.

    Time frame: Through study completion, an average of 1 year.

  5. Situation related to economic activity

    Economic activity according to the 7 categories: working, unemployed, retired, studying, unable to work, mainly engaged in housework and other situations.

    Time frame: Through study completion, an average of 1 year.

  6. Working time

    If working, type of working time according to the categories: full time and part time.

    Time frame: Through study completion, an average of 1 year.

  7. Time since the prescription of the medicine

    Time in months.

    Time frame: Through study completion, an average of 1 year.

  8. Total number of medicines prescribed per day

    Number of medicines prescribed per day according to the categories: less than 5 medicines and more than 5.

    Time frame: Through study completion, an average of 1 year.

07

Study locations

1 site
  • Clinical Pharmacy and Pharmaceutical Care Unit.
    Barcelona, 08028, Spain
08

References and documents

Publications

  • Roudijk B, Ludwig K, Devlin N. EQ-5D-5L Value Set Summaries. 2022 Mar 24. In: Devlin N, Roudijk B, Ludwig K, editors. Value Sets for EQ-5D-5L: A Compendium, Comparative Review & User Guide [Internet]. Cham (CH): Springer; 2022. Chapter 4. Available from http://www.ncbi.nlm.nih.gov/books/NBK589305/ PubMed 36810042 ↗
  • Andreu-March M, Aguas Compaired M, Marino EL, Modamio P. Cross-cultural adaptation and validation of the Recognizing And Addressing Limited Pharmaceutical Literacy (RALPH) interview guide in community pharmacies. Res Social Adm Pharm. 2023 Jun;19(6):882-888. doi: 10.1016/j.sapharm.2023.02.004. Epub 2023 Feb 16. PubMed 36868912 ↗

Individual participant data

Plan to share: No — Acording to the protocol aproved by the Bioethics Commission of the University of Barcelona, the IPD will not be shared with other researchers since it is not an interventional study.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2024 (actual). Primary completion is estimated for Jun 2025, 7 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 21, 2024
First posted
Dec 11, 2024
StartActual
Nov 15, 2024
Primary completionEst.
Jun 30, 2025
CompletionEst.
Jul 30, 2025
Last update
Apr 13, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 13, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06729697
Collaborators
Sociedad Espanola de Farmacia Clinica, Familiar y Comunitaria
Responsible party
Pilar Modamio (Full Professor, University of Barcelona) — Principal investigator
First posted
Dec 11, 2024
Start date
Nov 15, 2024
Primary completion
Jun 30, 2025 (estimated)
Completion
Jul 30, 2025 (estimated)
Last update
Apr 13, 2025

Study contacts

Pilar Modamio Charles, PhD
study director · University of Barcelona

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion